Insider Transactions in Q2 2022 at Cti Biopharma Corp (CTIC)
Insider Transaction List (Q2 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 30
2022
|
David Kirske EVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,516
+36.01%
|
$19,032
$2.12 P/Share
|
|
Jun 30
2022
|
Adam R Craig President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
6,183
+21.29%
|
$12,366
$2.12 P/Share
|
|
Jun 17
2022
|
David Kirske EVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
60,000
-72.3%
|
$360,000
$6.13 P/Share
|
|
Jun 17
2022
|
David Kirske EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
60,000
+41.53%
|
$120,000
$2.15 P/Share
|
|
Jun 14
2022
|
David Kirske EVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
10,000
-57.48%
|
$50,000
$5.5 P/Share
|
|
Jun 14
2022
|
David Kirske EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+36.5%
|
$0
$0.95 P/Share
|
|
Jun 03
2022
|
Adam R Craig President and CEO |
SELL
Open market or private sale
|
Direct |
18,223
-52.21%
|
$109,338
$6.01 P/Share
|
|
Jun 03
2022
|
Adam R Craig President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
18,223
+34.3%
|
$0
$0.84 P/Share
|
|
Jun 02
2022
|
Adam R Craig President and CEO |
SELL
Open market or private sale
|
Direct |
27,000
-61.82%
|
$162,000
$6.0 P/Share
|
|
Jun 02
2022
|
Adam R Craig President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
27,000
+38.2%
|
$0
$0.84 P/Share
|
|
Jun 01
2022
|
Adam R Craig President and CEO |
SELL
Open market or private sale
|
Direct |
27,000
-61.82%
|
$162,000
$6.0 P/Share
|
|
Jun 01
2022
|
Adam R Craig President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
27,000
+38.2%
|
$0
$0.84 P/Share
|